Global Tumor Necrosis Factor Inhibitors Market Insights and Forecast to 2031

Report ID: 1564596 | Published Date: Sep 2024 | No. of Page: 110 | Base Year: 2023 | Rating: 4.4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Tumor Necrosis Factor Inhibitors Product Introduction
    1.2 Market by Type
        1.2.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Humira
        1.2.3 Enbrel
        1.2.4 Remicade
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Alzheimer's Diseases
        1.3.3 Parkinson's Diseases
        1.3.4 Ischemic Stroke
        1.3.5 Multiple Sclerosis
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Tumor Necrosis Factor Inhibitors Sales Estimates and Forecasts 2017-2028
    2.2 Global Tumor Necrosis Factor Inhibitors Revenue Estimates and Forecasts 2017-2028
    2.3 Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Tumor Necrosis Factor Inhibitors Sales by Region
        2.4.1 Global Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022)
        2.4.2 Global Sales Tumor Necrosis Factor Inhibitors by Region (2023-2028)
    2.5 Global Tumor Necrosis Factor Inhibitors Revenue by Region
        2.5.1 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022)
        2.5.2 Global Tumor Necrosis Factor Inhibitors Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers
        3.1.1 Global Top Tumor Necrosis Factor Inhibitors Manufacturers by Sales (2017-2022)
        3.1.2 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Tumor Necrosis Factor Inhibitors in 2021
    3.2 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
        3.2.1 Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2017-2022)
        3.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Revenue in 2021
    3.3 Global Tumor Necrosis Factor Inhibitors Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Tumor Necrosis Factor Inhibitors Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Tumor Necrosis Factor Inhibitors Sales by Type
        4.1.1 Global Tumor Necrosis Factor Inhibitors Historical Sales by Type (2017-2022)
        4.1.2 Global Tumor Necrosis Factor Inhibitors Forecasted Sales by Type (2023-2028)
        4.1.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    4.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type
        4.2.1 Global Tumor Necrosis Factor Inhibitors Historical Revenue by Type (2017-2022)
        4.2.2 Global Tumor Necrosis Factor Inhibitors Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    4.3 Global Tumor Necrosis Factor Inhibitors Price by Type
        4.3.1 Global Tumor Necrosis Factor Inhibitors Price by Type (2017-2022)
        4.3.2 Global Tumor Necrosis Factor Inhibitors Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Tumor Necrosis Factor Inhibitors Sales by Application
        5.1.1 Global Tumor Necrosis Factor Inhibitors Historical Sales by Application (2017-2022)
        5.1.2 Global Tumor Necrosis Factor Inhibitors Forecasted Sales by Application (2023-2028)
        5.1.3 Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    5.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application
        5.2.1 Global Tumor Necrosis Factor Inhibitors Historical Revenue by Application (2017-2022)
        5.2.2 Global Tumor Necrosis Factor Inhibitors Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    5.3 Global Tumor Necrosis Factor Inhibitors Price by Application
        5.3.1 Global Tumor Necrosis Factor Inhibitors Price by Application (2017-2022)
        5.3.2 Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Tumor Necrosis Factor Inhibitors Market Size by Type
        6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
        6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
    6.2 North America Tumor Necrosis Factor Inhibitors Market Size by Application
        6.2.1 North America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
        6.2.2 North America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
    6.3 North America Tumor Necrosis Factor Inhibitors Market Size by Country
        6.3.1 North America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
        6.3.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Tumor Necrosis Factor Inhibitors Market Size by Type
        7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
        7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
    7.2 Europe Tumor Necrosis Factor Inhibitors Market Size by Application
        7.2.1 Europe Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
        7.2.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
    7.3 Europe Tumor Necrosis Factor Inhibitors Market Size by Country
        7.3.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
        7.3.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Type
        8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
        8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
    8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Application
        8.2.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
        8.2.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
    8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size by Region
        8.3.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2017-2028)
        8.3.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Tumor Necrosis Factor Inhibitors Market Size by Type
        9.1.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
        9.1.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
    9.2 Latin America Tumor Necrosis Factor Inhibitors Market Size by Application
        9.2.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
        9.2.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
    9.3 Latin America Tumor Necrosis Factor Inhibitors Market Size by Country
        9.3.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
        9.3.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Type
        10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2028)
    10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Application
        10.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2028)
    10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size by Country
        10.3.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 EPIRUS Biopharmaceuticals
        11.1.1 EPIRUS Biopharmaceuticals Corporation Information
        11.1.2 EPIRUS Biopharmaceuticals Overview
        11.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 EPIRUS Biopharmaceuticals Recent Developments
    11.2 Bionovis
        11.2.1 Bionovis Corporation Information
        11.2.2 Bionovis Overview
        11.2.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Bionovis Recent Developments
    11.3 CASI Pharmaceuticals
        11.3.1 CASI Pharmaceuticals Corporation Information
        11.3.2 CASI Pharmaceuticals Overview
        11.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 CASI Pharmaceuticals Recent Developments
    11.4 Janssen Biotech
        11.4.1 Janssen Biotech Corporation Information
        11.4.2 Janssen Biotech Overview
        11.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Janssen Biotech Recent Developments
    11.5 Momenta Pharmaceuticals
        11.5.1 Momenta Pharmaceuticals Corporation Information
        11.5.2 Momenta Pharmaceuticals Overview
        11.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Momenta Pharmaceuticals Recent Developments
    11.6 GlaxoSmithKline
        11.6.1 GlaxoSmithKline Corporation Information
        11.6.2 GlaxoSmithKline Overview
        11.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 GlaxoSmithKline Recent Developments
    11.7 HanAll Biopharma
        11.7.1 HanAll Biopharma Corporation Information
        11.7.2 HanAll Biopharma Overview
        11.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 HanAll Biopharma Recent Developments
    11.8 Intas Pharmaceuticals
        11.8.1 Intas Pharmaceuticals Corporation Information
        11.8.2 Intas Pharmaceuticals Overview
        11.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Intas Pharmaceuticals Recent Developments
    11.9 LEO Pharma
        11.9.1 LEO Pharma Corporation Information
        11.9.2 LEO Pharma Overview
        11.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 LEO Pharma Recent Developments
    11.10 Dexa Medica
        11.10.1 Dexa Medica Corporation Information
        11.10.2 Dexa Medica Overview
        11.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Dexa Medica Recent Developments
    11.11 LG Life Sciences
        11.11.1 LG Life Sciences Corporation Information
        11.11.2 LG Life Sciences Overview
        11.11.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 LG Life Sciences Recent Developments
    11.12 MedImmune
        11.12.1 MedImmune Corporation Information
        11.12.2 MedImmune Overview
        11.12.3 MedImmune Tumor Necrosis Factor Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 MedImmune Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 MedImmune Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Tumor Necrosis Factor Inhibitors Industry Chain Analysis
    12.2 Tumor Necrosis Factor Inhibitors Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Tumor Necrosis Factor Inhibitors Production Mode & Process
    12.4 Tumor Necrosis Factor Inhibitors Sales and Marketing
        12.4.1 Tumor Necrosis Factor Inhibitors Sales Channels
        12.4.2 Tumor Necrosis Factor Inhibitors Distributors
    12.5 Tumor Necrosis Factor Inhibitors Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Tumor Necrosis Factor Inhibitors Industry Trends
    13.2 Tumor Necrosis Factor Inhibitors Market Drivers
    13.3 Tumor Necrosis Factor Inhibitors Market Challenges
    13.4 Tumor Necrosis Factor Inhibitors Market Restraints
14 Key Findings in The Global Tumor Necrosis Factor Inhibitors Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Humira
    Table 3. Major Manufacturers of Enbrel
    Table 4. Major Manufacturers of Remicade
    Table 5. Major Manufacturers of Others
    Table 6. Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Tumor Necrosis Factor Inhibitors Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022) & (K Pcs)
    Table 9. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2017-2022)
    Table 10. Global Tumor Necrosis Factor Inhibitors Sales by Region (2023-2028) & (K Pcs)
    Table 11. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2023-2028)
    Table 12. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2017-2022)
    Table 14. Global Tumor Necrosis Factor Inhibitors Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2023-2028)
    Table 16. Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 17. Global Tumor Necrosis Factor Inhibitors Sales Share by Manufacturers (2017-2022)
    Table 18. Global Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2017-2022)
    Table 20. Tumor Necrosis Factor Inhibitors Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 21. Global Tumor Necrosis Factor Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Tumor Necrosis Factor Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitors as of 2021)
    Table 23. Tumor Necrosis Factor Inhibitors Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Tumor Necrosis Factor Inhibitors Product Offered
    Table 25. Date of Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 28. Global Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 29. Global Tumor Necrosis Factor Inhibitors Sales Share by Type (2017-2022)
    Table 30. Global Tumor Necrosis Factor Inhibitors Sales Share by Type (2023-2028)
    Table 31. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Tumor Necrosis Factor Inhibitors Revenue Share by Type (2017-2022)
    Table 34. Global Tumor Necrosis Factor Inhibitors Revenue Share by Type (2023-2028)
    Table 35. Tumor Necrosis Factor Inhibitors Price by Type (2017-2022) & (USD/Pcs)
    Table 36. Global Tumor Necrosis Factor Inhibitors Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 37. Global Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 38. Global Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 39. Global Tumor Necrosis Factor Inhibitors Sales Share by Application (2017-2022)
    Table 40. Global Tumor Necrosis Factor Inhibitors Sales Share by Application (2023-2028)
    Table 41. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 42. Global Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 43. Global Tumor Necrosis Factor Inhibitors Revenue Share by Application (2017-2022)
    Table 44. Global Tumor Necrosis Factor Inhibitors Revenue Share by Application (2023-2028)
    Table 45. Tumor Necrosis Factor Inhibitors Price by Application (2017-2022) & (USD/Pcs)
    Table 46. Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 47. North America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 48. North America Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 49. North America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 52. North America Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 53. North America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 54. North America Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 55. North America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)
    Table 56. North America Tumor Necrosis Factor Inhibitors Sales by Country (2023-2028) & (K Pcs)
    Table 57. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 60. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 61. Europe Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 64. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 65. Europe Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 66. Europe Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 67. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)
    Table 68. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2023-2028) & (K Pcs)
    Table 69. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 72. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 73. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 76. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 77. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2017-2022) & (K Pcs)
    Table 80. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2023-2028) & (K Pcs)
    Table 81. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 84. Latin America Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 85. Latin America Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 88. Latin America Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 89. Latin America Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 90. Latin America Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 91. Latin America Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)
    Table 92. Latin America Tumor Necrosis Factor Inhibitors Sales by Country (2023-2028) & (K Pcs)
    Table 93. Latin America Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Tumor Necrosis Factor Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Type (2017-2022) & (K Pcs)
    Table 96. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Type (2023-2028) & (K Pcs)
    Table 97. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Application (2017-2022) & (K Pcs)
    Table 100. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Application (2023-2028) & (K Pcs)
    Table 101. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Application (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Application (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2017-2022) & (K Pcs)
    Table 104. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2023-2028) & (K Pcs)
    Table 105. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2023-2028) & (US$ Million)
    Table 107. EPIRUS Biopharmaceuticals Corporation Information
    Table 108. EPIRUS Biopharmaceuticals Description and Major Businesses
    Table 109. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 110. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. EPIRUS Biopharmaceuticals Recent Developments
    Table 112. Bionovis Corporation Information
    Table 113. Bionovis Description and Major Businesses
    Table 114. Bionovis Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 115. Bionovis Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Bionovis Recent Developments
    Table 117. CASI Pharmaceuticals Corporation Information
    Table 118. CASI Pharmaceuticals Description and Major Businesses
    Table 119. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 120. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. CASI Pharmaceuticals Recent Developments
    Table 122. Janssen Biotech Corporation Information
    Table 123. Janssen Biotech Description and Major Businesses
    Table 124. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 125. Janssen Biotech Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Janssen Biotech Recent Developments
    Table 127. Momenta Pharmaceuticals Corporation Information
    Table 128. Momenta Pharmaceuticals Description and Major Businesses
    Table 129. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 130. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Momenta Pharmaceuticals Recent Developments
    Table 132. GlaxoSmithKline Corporation Information
    Table 133. GlaxoSmithKline Description and Major Businesses
    Table 134. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 135. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. GlaxoSmithKline Recent Developments
    Table 137. HanAll Biopharma Corporation Information
    Table 138. HanAll Biopharma Description and Major Businesses
    Table 139. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 140. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 141. HanAll Biopharma Recent Developments
    Table 142. Intas Pharmaceuticals Corporation Information
    Table 143. Intas Pharmaceuticals Description and Major Businesses
    Table 144. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 145. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 146. Intas Pharmaceuticals Recent Developments
    Table 147. LEO Pharma Corporation Information
    Table 148. LEO Pharma Description and Major Businesses
    Table 149. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 150. LEO Pharma Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 151. LEO Pharma Recent Developments
    Table 152. Dexa Medica Corporation Information
    Table 153. Dexa Medica Description and Major Businesses
    Table 154. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 155. Dexa Medica Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 156. Dexa Medica Recent Developments
    Table 157. LG Life Sciences Corporation Information
    Table 158. LG Life Sciences Description and Major Businesses
    Table 159. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 160. LG Life Sciences Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 161. LG Life Sciences Recent Developments
    Table 162. MedImmune Corporation Information
    Table 163. MedImmune Description and Major Businesses
    Table 164. MedImmune Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 165. MedImmune Tumor Necrosis Factor Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications
    Table 166. MedImmune Recent Developments
    Table 167. Key Raw Materials Lists
    Table 168. Raw Materials Key Suppliers Lists
    Table 169. Tumor Necrosis Factor Inhibitors Distributors List
    Table 170. Tumor Necrosis Factor Inhibitors Customers List
    Table 171. Tumor Necrosis Factor Inhibitors Market Trends
    Table 172. Tumor Necrosis Factor Inhibitors Market Drivers
    Table 173. Tumor Necrosis Factor Inhibitors Market Challenges
    Table 174. Tumor Necrosis Factor Inhibitors Market Restraints
    Table 175. Research Programs/Design for This Report
    Table 176. Key Data Information from Secondary Sources
    Table 177. Key Data Information from Primary Sources
List of Figures
    Figure 1. Tumor Necrosis Factor Inhibitors Product Picture
    Figure 3. Global Tumor Necrosis Factor Inhibitors Market Share by Type in 2021 & 2028
    Figure 3. Humira Product Picture
    Figure 4. Enbrel Product Picture
    Figure 5. Remicade Product Picture
    Figure 6. Others Product Picture
    Figure 7. Global Tumor Necrosis Factor Inhibitors Market Share by Application in 2021 & 2028
    Figure 8. Alzheimer's Diseases
    Figure 9. Parkinson's Diseases
    Figure 10. Ischemic Stroke
    Figure 11. Multiple Sclerosis
    Figure 12. Others
    Figure 13. Tumor Necrosis Factor Inhibitors Report Years Considered
    Figure 14. Global Tumor Necrosis Factor Inhibitors Sales 2017-2028 (K Pcs)
    Figure 15. Global Tumor Necrosis Factor Inhibitors Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Tumor Necrosis Factor Inhibitors Revenue 2017-2028 (US$ Million)
    Figure 17. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2017-2022)
    Figure 19. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2023-2028)
    Figure 20. North America Tumor Necrosis Factor Inhibitors Sales YoY (2017-2028) & (K Pcs)
    Figure 21. North America Tumor Necrosis Factor Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Tumor Necrosis Factor Inhibitors Sales YoY (2017-2028) & (K Pcs)
    Figure 23. Europe Tumor Necrosis Factor Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific Tumor Necrosis Factor Inhibitors Sales YoY (2017-2028) & (K Pcs)
    Figure 25. Asia-Pacific Tumor Necrosis Factor Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America Tumor Necrosis Factor Inhibitors Sales YoY (2017-2028) & (K Pcs)
    Figure 27. Latin America Tumor Necrosis Factor Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa Tumor Necrosis Factor Inhibitors Sales YoY (2017-2028) & (K Pcs)
    Figure 29. Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The Tumor Necrosis Factor Inhibitors Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of Tumor Necrosis Factor Inhibitors in the World: Market Share by Tumor Necrosis Factor Inhibitors Revenue in 2021
    Figure 32. Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 34. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 35. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 36. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 37. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 38. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 39. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 40. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 41. North America Tumor Necrosis Factor Inhibitors Sales Share by Country (2017-2028)
    Figure 42. North America Tumor Necrosis Factor Inhibitors Revenue Share by Country (2017-2028)
    Figure 43. U.S. Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 46. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 47. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 48. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 49. Europe Tumor Necrosis Factor Inhibitors Sales Share by Country (2017-2028)
    Figure 50. Europe Tumor Necrosis Factor Inhibitors Revenue Share by Country (2017-2028)
    Figure 51. Germany Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 52. France Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 53. U.K. Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 54. Italy Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 55. Russia Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 56. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 58. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 60. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Share by Region (2017-2028)
    Figure 61. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Share by Region (2017-2028)
    Figure 62. China Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 63. Japan Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 64. South Korea Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 65. India Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 66. Australia Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 67. Taiwan Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 68. Indonesia Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 69. Thailand Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 70. Malaysia Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 71. Philippines Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 72. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 73. Latin America Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 74. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 75. Latin America Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 76. Latin America Tumor Necrosis Factor Inhibitors Sales Share by Country (2017-2028)
    Figure 77. Latin America Tumor Necrosis Factor Inhibitors Revenue Share by Country (2017-2028)
    Figure 78. Mexico Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 79. Brazil Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 80. Argentina Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 81. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2017-2028)
    Figure 83. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2017-2028)
    Figure 85. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Share by Country (2017-2028)
    Figure 86. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Share by Country (2017-2028)
    Figure 87. Turkey Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 88. Saudi Arabia Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 89. UAE Tumor Necrosis Factor Inhibitors Revenue (2017-2028) & (US$ Million)
    Figure 90. Tumor Necrosis Factor Inhibitors Value Chain
    Figure 91. Tumor Necrosis Factor Inhibitors Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
EPIRUS Biopharmaceuticals
Bionovis
CASI Pharmaceuticals
Janssen Biotech
Momenta Pharmaceuticals
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
Dexa Medica
LG Life Sciences
MedImmune
Frequently Asked Questions
Tumor Necrosis Factor Inhibitors report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Tumor Necrosis Factor Inhibitors report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Tumor Necrosis Factor Inhibitors report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Immunotoxins

Immunotoxins market is segmented by Type and by Application. Players, stakeholders, and other par ... Read More